Search Results for:
-
Other News To Note
after approval by the FDA in February, and the compound is under review by the European Medicines AgencyBioWorld International | Wednesday, June 19, 2013 -
Campaign to Boost 'RAIT' of Clinical Data Transparency
If those companies do not comply, Doshi and fellow campaigners said they will publish documents released by the European Medicines Agency (EMA) following freedom-of-information requests, or as part of litigation over off-label marketingBy Nuala Moran | BioWorld International | Wednesday, June 19, 2013 -
Clinic Roundup
after approval by the FDA in February, and the compound is under review by the European Medicines Agency. (See BioWorld Today, Feb. 11, 2013BioWorld Today | Monday, June 17, 2013 -
Other News To Note
Cangene Corp., of Winnipeg, Manitoba, said it withdrew its marketing authorization application for hemophilia compound IB1001 in Europe and intends to refile the application with the additional clinical data requested by the European Medicines AgencyBioWorld Today | Monday, June 17, 2013 -
Non-U.S. Clinical Trials & Regulatory Actions: May 2013
EMA = European Medicines AgencyBioWorld Insight | Monday, June 17, 2013 -
Clinic Roundup
Nanobiotix, of Paris, received authorization from the French Medicine Agency to begin a Phase I trial of NBTXR3 in head and neck cancerBioWorld Today | Friday, June 14, 2013 -
Clinic Roundup
The results form the basis of the company's ongoing efforts to pursue a marketing application authorization with the European Medicine Agency under the exceptional circumstances process, which is specifically designated for very rare diseases that have limited or no available therapeutic options and a significant unmet medical needBioWorld Today | Tuesday, June 11, 2013 -
Aveo Receives CRL from FDA After Stopping RCC Program
A few weeks after the ODAC meeting Aveo's partner Astellas said it didn't intend to submit a marketing authorization application to the European Medicines Agency for tivozanib for the treatment of RCC patients or fund any future trials in RCC under the firms' strategic collaboration inked in February 2011. (See BioWorld Today, May 28, 2013.) RBC Capital Markets LLC analyst Michael Yee wrote in a research note that Astellas' decision to drop the kidney cancer indication was not unexpectedBy Peter Winter | BioWorld Today | Tuesday, June 11, 2013 -
AVEO Terminates RCC Program, Cuts Workforce to Conserve Cash
A few weeks after the ODAC meeting AVEO's partner Astellas Pharma Inc., of Tokyo, said it didn't intend to submit a marketing authorization application to the European Medicines Agency for tivozanib for the treatment of RCC patients or fund any future trials in RCC under the firms' strategic collaboration inked in February 2011. (See BioWorld Today, May 28, 2013.) RBC Capital Markets LLC analyst Michael Yee said in a research note that Astellas' decision to drop the kidney cancer indication wasBy Peter Winter | BioWorld Insight | Monday, June 10, 2013 -
Other News To Note
Ltd., of Tokyo, submitted a type-II variation to the European Medicines Agency (EMA) for Rienso (ferumoxytolBioWorld Today | Monday, June 10, 2013 -
BioMarin Launches Phase III Program for Phenylketonuria
The company also submitted a marketing authorization application to the European Medicines Agency for VimizimBy Catherine Shaffer | BioWorld Today | Thursday, June 6, 2013 -
Other News To Note
The Committee for Medicinal Products for Human Use of the European Medicines Agency gave a positive opinion on granting marketing authorization to Bavarian Nordic A/S, of Kvistgard, Denmark, for Imvanex, a smallpox vaccination for the general adult population, including those with immunodeficiencies...Celgene International Sarl, of Boudry, Switzerland, a subsidiary of Celgene Corp., said the European Medicines Agency's (EMA): Committee for Medicinal Products for Human Use (CHMP) has adopted aBioWorld International | Wednesday, June 5, 2013 -
Other News To Note
The Committee for Medicinal Products for Human Use of the European Medicines Agency gave a positive opinion on granting marketing authorization to Bavarian Nordic A/S, of Kvistgard, Denmark, for Imvanex, a smallpox vaccination for the general adult population, including those with immunodeficiencies...Novo Nordisk A/S, of Bagsvaerd, Denmark, applied to the European Medicines Agency for marketing authorization of IdegLira, a combination of insulin degludec (Tresiba) and liraglutide (Victoza), forBioWorld Today | Monday, June 3, 2013 -
GSK Partnership 'Catapults' Cell Therapy Projects in UK
In addition to technical issues such as scaling up and the development of release assays for quality control, GSK has an interest in work the Catapult is doing with the UK Medicines and Healthcare Products Regulatory Agency and the European Medicines Agency on defining the regulatory requirements to move cell therapies forwardBy Nuala Moran | BioWorld International | Wednesday, May 29, 2013 -
Clinical Failures Mark End for Agennix, Phytopharm
The company moved its headquarters to Germany when it merged with GPC Biotech AG, of Martinsried, Germany, in November 2009, after GPC came unstuck over the European Medicines Agency's refusal to approve its cancer drug satraplatin, an orally delivered platinum compoundBy Nuala Moran | BioWorld International | Wednesday, May 29, 2013 -
Other News To Note
3SBio Inc., of Shenyang, China, said its shareholders voted in favor of the proposal to merge with Decade Sunshine Ltd. The merger would result in 3SBio becoming a privately held subsidiary of Decade Sunshine, with its American depository shares no longer listed on Nasdaq. The company's board previously recommended that shareholders vote to authorize the merger, and the parties expect to complete the deal as soon as practicable. Addex Therapeutics SA, of Geneva, said its gamma-aminobutyricBioWorld International | Wednesday, May 29, 2013 -
Clinical Failures Mark End for Agennix, Phytopharm
The company moved its headquarters to Germany when it merged with GPC Biotech AG, of Martinsried, Germany, in November 2009, after GPC came unstuck over the European Medicines Agency's refusal to approve its cancer drug satraplatin, an orally delivered platinum compoundBy Nuala Moran | BioWorld Today | Wednesday, May 29, 2013 -
Other News To Note
AVEO Pharmaceuticals Inc., of Cambridge, Mass., said in an SEC filing that it was informed by partner Astellas Pharma Inc., of Tokyo, that Astellas no longer intends to submit a marketing authorization application to the European Medicines Agency for tivozanib for the treatment of patients with advanced renal cell carcinoma (RCCBioWorld Today | Tuesday, May 28, 2013 -
Other News To Note
Gilead Sciences Inc., of Foster City, Calif., said its marketing authorization application (MAA) for sofosbuvir was validated by the European Medicines Agency (EMA) and is under assessment...Veloxis Pharmaceuticals A/S, of Horsholm, Denmark, said the European Medicines Agency agreed to review its marketing authorization application for LCP-Tacro to prevent organ rejection in kidney transplant patientsBioWorld Today | Thursday, May 23, 2013 -
As Markets Fancy Biotech, PTC Therapeutics Joins IPO Queue
Last month, PTC initiated a confirmatory Phase III trial of ataluren in nmDMD, following submission of a marketing authorization application to the European Medicines Agency in October 2012 seeking conditional approval...The drug has orphan drug status from the FDA and orphan medicinal product status from the European Medicines Agency in both nmDMD and nmCFBy Marie Powers | BioWorld Today | Monday, May 20, 2013
Category
Current Filters
- xMedicines Agency
Related Keywords
Categories
- x BioWorld Today (734)
- x BioWorld International (432)
- x BioWorld Insight (140)
- x Bio Perspectives (43)
- x State of the Industry Report (11)
- x Top 25 Drug Report (8)
- x BioWorld Phase III Report (1)
- x Market-Leading Biotech Drugs (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.